NCT01217931进行中（未招募）2 期
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Time to Overall Treatment Failure
研究概览
简要总结
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after that. Researchers will also study the safety of these 2-drug sequences.
详细描述
The Study Drugs:
Everolimus is designed to block the growth of cancer cells, which may cause cancer cells to die.
Bevacizumab is designed to block the growth of blood vessels that supply nutrients necessary for tumor growth. This may prevent or slow down the growth of cancer cells.
Pazopanib is designed to block a protein that may cause uncontrolled tumor growth. Blocking this protein may prevent cancer from growing and spreading.
Study Drug Administration:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Confirmed metastatic RCC with a clear cell component.
- •2. Prior radical or partial nephrectomy required. Patients whose primary tumor was treated with cryoablation or radiofrequency ablation would also be eligible.
- •3. Measurable disease
- •4. Age \>/= 18 years. Because no dosing or adverse event data are currently available on the use of these targeted agents in patients \< 18 years of age, children are excluded from this study
- •5. ECOG performance status 0 or 1
- •6. Adequate organ and marrow function within 14 days as defined below: a) Absolute neutrophil count /=\> 1,500/microL; b) Platelets \>/= 100,000/microL; c) Hgb \>/= 9.0 g/dL (transfusion allowed); d) Total bilirubin \< 1.5 mg/dl; e) Albumin \> 2.5 g/dL; f) AST and ALT \/= 50 cc/min; i) Fasting serum cholesterol \
排除标准
- •No patient with any concurrent active malignancy, i.e. a patient requiring or receiving systemic therapy for another malignancy at the same time of treatment for RCC
- •Patients must not have received any prior targeted therapy (anti-VEGF agents or mTOR inhibitors), including adjuvant therapy, and must not have received any prior chemotherapy for mRCC. However, patients who had received prior immunotherapy, such as cytokines or vaccines, are permitted to enroll.
- •Patients must not be scheduled to receive another experimental drug while on this study. Patients are permitted to receive concomitant bisphosphonates.
- •Patients must not have multiple brain metastases or leptomeningeal disease. Patients with controlled solitary brain metastasis are eligible.
- •Patients must not have had a stroke or transient ischemic attack within 6 months.
- •Patients must not have uncontrolled infections.
- •Patients must not have clinically significant cardiovascular disease, defined as myocardial infarction (or unstable angina) within 6 months, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia refractory to medical management
- •Patients must not have uncontrolled hypertension, defined as > 140/90 or prior history of hypertensive crisis or hypertensive encephalopathy. Treatment of hypertension with medications is permitted.
- •History of hemoptysis (>/= 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
- •Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- •Symptomatic peripheral vascular disease
- •Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breast-feeding should be discontinued if the mother is enrolled on this trial.
- •Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. Therefore, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with some of these agents.
- •Patients must not have a clinical history of coagulopathy or bleeding diathesis. Patients may be on therapeutic anticoagulation preferably a low-molecular weight heparin. If the patients are on warfarin, the INR should be maintained within a therapeutic level and must be checked weekly for the first four weeks, then every 2 weeks for 4 additional weeks. Thereafter, they may be followed at the discretion of the treating provider. Antiplatelet agents are allowed.
- •Concomitant treatment with rifampin, St. John's wort, or the cytochrome p450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or Phenobarbital) is not allowed on this study.
- •Patients with significant baseline proteinuria defined as 300 or greater by screening U/A will be excluded if they have > 1,000 mg proteins in a 24-hour urine collection or if they have a random urine protein over creatinine (UPC) ratio >
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- •Serious, non-healing wound, ulcer, or bone fracture
- •Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
- •Known hypersensitivity to any component of bevacizumab, pazopanib or everolimus.
- •Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus. Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.
- •Patients with severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
- •Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C). Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.
- •Patients receiving chronic, systemic treatment with steroids in pharmacological doses or immunosuppressive agents are excluded. Patients who receive steroids for physiological replacement, e.g., after adrenalectomy are not excluded. Topical or inhaled corticosteroids are also allowed.
研究组 & 干预措施
Group 3
Experimental
Everolimus + possible Bevacizumab
干预措施: Bevacizumab (Drug)
Group 6
Experimental
Bevacizumab + possible Everolimus
干预措施: Everolimus (Drug)
Group 1
Experimental
Pazopanib + possible Bevacizumab
干预措施: Pazopanib (Drug)
Group 2
Experimental
Pazopanib + possible Everolimus
干预措施: Pazopanib (Drug)
Group 2
Experimental
Pazopanib + possible Everolimus
干预措施: Everolimus (Drug)
Group 1
Experimental
Pazopanib + possible Bevacizumab
干预措施: Bevacizumab (Drug)
Group 4
Experimental
Everolimus + possible Pazopanib
干预措施: Pazopanib (Drug)
Group 3
Experimental
Everolimus + possible Bevacizumab
干预措施: Everolimus (Drug)
Group 6
Experimental
Bevacizumab + possible Everolimus
干预措施: Bevacizumab (Drug)
Group 5
Experimental
Bevacizumab + possible Pazopanib
干预措施: Bevacizumab (Drug)
Group 4
Experimental
Everolimus + possible Pazopanib
干预措施: Everolimus (Drug)
结局指标
主要结局
Time to Overall Treatment Failure
时间窗: 4 weeks
Measured from date of randomization to date of second disease progression, 'drop-out' from protocol treatment for any reason or death, associated with each of the six two-agent sequential therapies given in parallel.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid CancerThyroid CancerNCT01270321Emory University42
已完成
2 期
Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT01491672Novartis Pharmaceuticals134
已完成
不适用
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist BasiliximabRenal TransplantationNCT00842699Brigham and Women's Hospital40
进行中（未招募）
2 期
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Metastatic Renal Cell CarcinomaNCT06284564M.D. Anderson Cancer Center10
进行中（未招募）
2 期
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial CancerAdvanced, Persistent, or Recurrent Endometrial CancerNCT02228681GOG Foundation74